These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 2502523)
1. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas. Kuroki Y; Shimoyama M; Inaba S; Hirose M Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523 [TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin. Agarwal RP; Blatt J; Miser J; Sallan S; Lipton JM; Reaman GH; Holcenberg J; Poplack DG Cancer Res; 1982 Sep; 42(9):3884-6. PubMed ID: 6980706 [TBL] [Abstract][Full Text] [Related]
3. 2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia. Gray DP; Grever MR; Siaw MF; Coleman MS; Balcerzak SP Cancer Treat Rep; 1982 Feb; 66(2):253-7. PubMed ID: 6976833 [TBL] [Abstract][Full Text] [Related]
4. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes. Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772 [TBL] [Abstract][Full Text] [Related]
5. Opposite effects of recombinant interferon-alpha A and deoxycoformycin on adenosine deaminase activity in the Daudi B lymphoblastoid cell line. Faltynek CR Blood; 1988 Jan; 71(1):59-64. PubMed ID: 3257147 [TBL] [Abstract][Full Text] [Related]
6. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine. Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986 [TBL] [Abstract][Full Text] [Related]
7. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine. Plunkett W; Benjamin RS; Keating MJ; Freireich EJ Cancer Res; 1982 May; 42(5):2092-6. PubMed ID: 6175407 [TBL] [Abstract][Full Text] [Related]
8. Therapy with 9-beta-D-arabinofuranosyladenine (ARA-A) and 2'-deoxycoformycin increases the ARA-A content of ocular tissues. O'Brien WJ Curr Eye Res; 1986 Aug; 5(8):595-9. PubMed ID: 3489583 [TBL] [Abstract][Full Text] [Related]
9. Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A). Yu AL; Mendelsohn J; Matsumoto SS Adv Exp Med Biol; 1986; 195 Pt A():491-6. PubMed ID: 3487920 [No Abstract] [Full Text] [Related]
10. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts. Holland MJ Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439 [TBL] [Abstract][Full Text] [Related]
11. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin. Cass CE; Au-Yeung TH Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the anti-herpesvirus drug combinations: virazole plus arabinofuranosylhypoxanthine and virazole plus arabinofuranosyladenine. Allen LB; Vanderslice LK; Fingal CM; McCright FH; Harris EF; Cook PD Antiviral Res; 1982 Sep; 2(4):203-16. PubMed ID: 6293375 [TBL] [Abstract][Full Text] [Related]
13. Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin. Schwartz CL; Minniti CP; Harwood P; Na S; Banquerigo ML; Strauss LC; Kurtzberg J; Smith SD; Civin CI J Clin Oncol; 1987 Dec; 5(12):1900-11. PubMed ID: 3500279 [TBL] [Abstract][Full Text] [Related]
14. Biochemical mechanisms of deoxycoformycin toxicity in chronic leukemias. Ganeshaguru K; Ho AD; Piga A; Catovsky D; Hoffbrand AV Leuk Res; 1987; 11(10):941-5. PubMed ID: 3500370 [TBL] [Abstract][Full Text] [Related]
15. Studies on the effect of deoxyadenosine on deoxycoformycin-treated myeloid and lymphoid stem cells. Aye MT; Dunne JV; Yang WC Blood; 1982 Oct; 60(4):872-6. PubMed ID: 6981441 [TBL] [Abstract][Full Text] [Related]
16. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response. Ho AD; Ganeshaguru K; Knauf W; Dietz G; Trede I; Hoffbrand AV; Hunstein W Leuk Res; 1989; 13(4):269-78. PubMed ID: 2785618 [TBL] [Abstract][Full Text] [Related]
17. Isolation of deoxycoformycin-resistant cells with increased levels of adenosine deaminase. Hoffee PA; Hunt SW; Chiang J Somatic Cell Genet; 1982 Jul; 8(4):465-77. PubMed ID: 6981855 [TBL] [Abstract][Full Text] [Related]
18. 2'-deoxycoformycin. A new anticancer agent. Poster DS; Penta JS; Bruno S; Macdonald JS Cancer Clin Trials; 1981; 4(2):209-13. PubMed ID: 7018725 [TBL] [Abstract][Full Text] [Related]
19. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture. Cass CE; Tan TH; Selner M Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484 [TBL] [Abstract][Full Text] [Related]
20. Reactivation of S-adenosylhomocysteine hydrolase activity in cells exposed to 9-beta-D-arabinofuranosyladenine. Helland S; Ueland PM Cancer Res; 1982 Jul; 42(7):2861-6. PubMed ID: 6979384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]